CLDX Celldex Therapeutics, Inc. Stock Quote

CLDX [NASD]

Index	-	P/E	-	EPS (ttm)	-1.71	Insider Own	0.21%	Shs Outstand	46.74M	Perf Week	3.14%
Market Cap	1.12B	Forward P/E	-	EPS next Y	-2.27	Insider Trans	0.00%	Shs Float	46.66M	Perf Month	14.63%
Income	-77.00M	PEG	-	EPS next Q	-0.51	Inst Own	-	Short Float	9.94%	Perf Quarter	-22.06%
Sales	4.10M	P/S	273.81	EPS this Y	18.40%	Inst Trans	8.18%	Short Ratio	6.72	Perf Half Y	-31.03%
Book/sh	8.52	P/B	3.16	EPS next Y	-12.80%	ROA	-20.10%	Target Price	64.83	Perf Year	-19.38%
Cash/sh	9.14	P/C	2.95	EPS next 5Y	-	ROE	-21.40%	52W Range	19.85 - 57.20	Perf YTD	-30.23%
Dividend	-	P/FCF	-	EPS past 5Y	38.70%	ROI	-16.90%	52W High	-59.63%	Beta	2.49
Dividend %	-	Quick Ratio	26.80	Sales past 5Y	-7.30%	Gross Margin	-	52W Low	16.32%	ATR	2.14
Employees	132	Current Ratio	26.80	Sales Q/Q	-71.40%	Oper. Margin	-	RSI (14)	41.22	Volatility	9.17% 8.10%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-18.10%	Profit Margin	-	Rel Volume	6.11	Prev Close	26.96
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	689.70K	Price	23.09
Recom	1.50	SMA20	-5.81%	SMA50	-16.19%	SMA200	-36.00%	Volume	3,567,289	Change	-14.35%

Sep-17-21

Initiated

Jefferies

Buy

$66

Sep-10-21

Initiated

SVB Leerink

Outperform

$68

Jul-22-21

Initiated

Guggenheim

Buy

$66

Feb-21-20

Initiated

Cantor Fitzgerald

Overweight

Aug-01-17

Resumed

H.C. Wainwright

Buy

$10

Nov-07-16

Initiated

Aegis Capital

Buy

Mar-08-16

Downgrade

Jefferies

Buy → Hold

Mar-07-16

Downgrade

Wedbush

Outperform → Neutral

Mar-07-16

Downgrade

Leerink Partners

Outperform → Mkt Perform

Mar-07-16

Downgrade

Guggenheim

Buy → Neutral

Mar-01-16

Initiated

H.C. Wainwright

Buy

$25

Aug-11-15

Reiterated

ROTH Capital

Buy

$43 → $39

Aug-11-15

Reiterated

Oppenheimer

Outperform

$45 → $42

Aug-11-15

Reiterated

Brean Capital

Buy

$35 → $31

Jun-02-15

Reiterated

WBB Securities

Strong Buy

$30 → $40

Nov-17-14

Reiterated

ROTH Capital

Buy

$40 → $43

Mar-04-14

Reiterated

Oppenheimer

Outperform

$40 → $36

Jul-08-13

Reiterated

Cantor Fitzgerald

Buy

$16 → $24

Mar-08-13

Reiterated

Cantor Fitzgerald

Buy

$13 → $16

Feb-26-13

Reiterated

Oppenheimer

Outperform

$10 → $13

Jul-01-22 10:11AM	Celldex's Barzolvolimab Shows Rapid, Durable Responses In Early Urticaria Study Benzinga -14.35%
10:11AM	Celldex Therapeutics Skids As It Takes On A Blockbuster Roche, Novartis Drug Investor's Business Daily
Jun-30-22 06:01PM	Celldex Therapeutics Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022 GlobeNewswire
Jun-22-22 09:24AM	Celldex (CLDX) Initiates Phase II Chronic Skin Disorder Study Zacks
Jun-21-22 08:00AM	Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria GlobeNewswire
Jun-20-22 10:35AM	We're Hopeful That Celldex Therapeutics (NASDAQ:CLDX) Will Use Its Cash Wisely Simply Wall St.
Jun-16-22 04:01PM	Celldex Announces Two New Appointments to its Board of Directors GlobeNewswire
Jun-06-22 04:05PM	Celldex to Present at the 2022 Jefferies Global Healthcare Conference GlobeNewswire
May-19-22 09:23AM	Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2022 GlobeNewswire
May-11-22 08:13AM	7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years InvestorPlace
May-06-22 08:10AM	Celldex Therapeutics' (NASDAQ:CLDX) investors will be pleased with their enviable 762% return over the last three years Simply Wall St.
May-05-22 05:55PM	Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates Zacks -5.57%
04:01PM	Celldex Reports First Quarter 2022 Financial Results and Provides Corporate Update GlobeNewswire
May-04-22 08:25AM	Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q1 Loss, Tops Revenue Estimates Zacks
Feb-28-22 04:01PM	Celldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update GlobeNewswire
Feb-22-22 04:01PM	Celldex to Host Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights Conference Call GlobeNewswire
Feb-17-22 03:07AM	Top 10 Biotech Stocks to Buy According to Jeremy Greens Redmile Group Insider Monkey -5.17%
Feb-13-22 07:47AM	Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 29%? Simply Wall St.
Feb-10-22 04:05PM	Celldex to Present at the 11th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-02-22 01:38PM	HC Advisors, LLC Buys Vanguard Short-Term Government Bond ETF, Apellis Pharmaceuticals Inc, ... GuruFocus.com
Jan-10-22 08:40AM	Is the Options Market Predicting a Spike in Celldex (CLDX) Stock? Zacks
Dec-15-21 04:57AM	We're Interested To See How Celldex Therapeutics (NASDAQ:CLDX) Uses Its Cash Hoard To Grow Simply Wall St.
01:38AM	VIP Growth Opportunities Portfolio Buys Uber Technologies Inc, Lightspeed Commerce Inc, Chewy ... GuruFocus.com
Dec-11-21 06:53PM	Hedge Funds Are Crazy About Celldex Therapeutics, Inc. (CLDX) Insider Monkey
Dec-08-21 08:01AM	Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis GlobeNewswire
Nov-12-21 07:00AM	Celldex Presents Positive Preclinical Data from PD-1/ILT4 Bispecific Antibody Program CDX-585 at SITC 2021 GlobeNewswire -5.47%
Nov-11-21 07:01AM	Celldex to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-09-21 06:15PM	Celldex Therapeutics (CLDX) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:01PM	Celldex Reports Third Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Oct-28-21 03:05PM	Celldex Therapeutics (CLDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
Oct-25-21 11:51AM	Should I Avoid Celldex Therapeutics, Inc. (CLDX)? Insider Monkey
Sep-29-21 08:13AM	The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug Benzinga
12:00AM	Celldex Presents Positive Data on Symptom Control and Quality of Life Measurements that Further Support CDX-0159 Clinical Benefit in Phase 1b Study in Chronic Inducible Urticaria at EADV 2021 GlobeNewswire
Sep-24-21 07:01AM	Celldex to Present at the 2021 Cantor Virtual Global Healthcare Conference GlobeNewswire
Sep-23-21 08:01AM	Celldex Announces Upcoming Presentation of CDX-0159 Phase 1b Results in Inducible Urticaria at the 2021 European Academy of Dermatology and Venereology (EADV) 30th Congress GlobeNewswire
Sep-16-21 07:01AM	Investors in Celldex Therapeutics (NASDAQ:CLDX) have made a enviable return of 729% over the past three years Simply Wall St.
Sep-14-21 10:31AM	Celldex (CLDX) Initiates Subcutaneous Skin Disorder Drug Study Zacks
Sep-13-21 09:01AM	Celldex Announces Initiation of CDX-0159 Subcutaneous Formulation Study GlobeNewswire
Aug-25-21 03:55PM	3 Strong Buy Stocks Showing Monster Growth TipRanks
Aug-05-21 06:05PM	Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates Zacks +6.38%
04:01PM	Celldex Reports Second Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Jul-29-21 03:05PM	Will Celldex Therapeutics (CLDX) Report Negative Q2 Earnings? What You Should Know Zacks
Jul-24-21 07:04AM	How Good Were Celldex Therapeutics' Latest Clinical Results? Motley Fool
Jul-18-21 03:39AM	What Is The Ownership Structure Like For Celldex Therapeutics, Inc. (NASDAQ:CLDX)? Simply Wall St.
Jul-16-21 04:01PM	Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire -7.34%
Jul-14-21 03:21PM	Biotech Stock Roundup: BIIB & PRTA Provide Updates, CLDX Up on Positive Data & More Zacks
08:39AM	Celldex (CLDX) Up Almost 40% Since Skin Disorder Study Data Zacks
06:41AM	Celldex Therapeutics Raises $250M Via Equity To Support Development Of Skin Disease Candidate Benzinga
Jul-13-21 08:30PM	Celldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common Stock GlobeNewswire +9.66%
03:19PM	Why Celldex Therapeutics Stock Is Jumping Again Today Motley Fool
Jul-12-21 04:27PM	Celldex Therapeutics Stock Rocketed Above A Profit-Taking Zone Here's Why Investor's Business Daily +25.49%
04:01PM	Celldex Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
03:54PM	You Should Know About Monday's 2 Big Nasdaq Winners Motley Fool
03:32PM	Where Do Hedge Funds Stand On Celldex Therapeutics, Inc. (CLDX)? Insider Monkey
11:09AM	Why Celldex Therapeutics Stock Is Skyrocketing Today Motley Fool
08:38AM	5 Top Stock Gainers for Monday: Celldex, Sgoco, State Auto TheStreet.com
07:44AM	Celldex's stock jumps on positive data from early-stage, open-label clinical trial for hives treatments MarketWatch
06:46AM	Celldex Soars On Positive Data From Early Trial For Hives Treatments Investing.com
06:12AM	Celldex Stock Surges As It Touts Early-Stage Skin Disease Study Win For CDX-0159 Benzinga
04:40AM	Premarket Movers Monday: Virgin Galactic, Apple, Sgoco, Celldex TheStreet.com
04:26AM	Celldex Jumps on Phase 1b Progress With Skin-Disorder Drug TheStreet.com
Jul-09-21 06:01PM	Celldex Therapeutics Presents Positive Data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria at EAACI 2021 GlobeNewswire
Jun-04-21 09:01AM	Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial at the 2021 ASCO Annual Meeting GlobeNewswire
Jun-01-21 07:31AM	Celldex Announces Acceptance of Abstract for CDX-0159 Phase 1b Results in Inducible Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021 GlobeNewswire
May-26-21 04:01PM	Celldex to Present at the Jefferies 2021 Virtual Healthcare Conference GlobeNewswire
May-13-21 03:18AM	We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth Simply Wall St.
May-06-21 06:35PM	Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:01PM	Celldex Reports First Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Apr-20-21 11:56AM	Is CLDX Stock A Buy or Sell? Insider Monkey
Apr-12-21 04:01PM	Celldex Presents Promising Data from ILT4/PD-(L)1 Bispecific Antibody Program at AACR 2021 GlobeNewswire
Apr-10-21 06:13AM	Could Celldex Be a Millionaire-Maker Stock? Motley Fool
Apr-06-21 09:05AM	ACADIA (ACAD) Gets CRL From FDA for Nuplazid sNDA, Shares Down Zacks -6.51%
Mar-29-21 04:01PM	Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2020 Results GlobeNewswire -13.81%
12:28PM	Why Is It Moving? Looking Into Why Celldex Therapeutics's Stock is Trading Lower Today Benzinga
12:06PM	Why Celldex Therapeutics Stock Is Tanking Today Motley Fool
07:35AM	Celldex's CDX-0159 Shows 80% Response Rate In Early-Stage Skin Allergy Study Benzinga
06:30AM	Celldex Reports 80% Complete Response Rate in Interim Data Update from Phase 1b study of CDX-0159 in Chronic Inducible Urticaria GlobeNewswire
Mar-05-21 01:00PM	Celldex Therapeutics Announces Fireside Chat Presentation at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire
Feb-23-21 06:01AM	Celldex Therapeutics To Test CDX-0159 In Chronic Itchy Skin Disorder Benzinga
Feb-22-21 04:01PM	Celldex Therapeutics to Expand Development of CDX-0159 into Prurigo Nodularis (PN) GlobeNewswire
08:01AM	Celldex Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Jan-26-21 12:39AM	Announcing: Celldex Therapeutics (NASDAQ:CLDX) Stock Soared An Exciting 736% In The Last Year Simply Wall St. +6.85%
Jan-08-21 08:51AM	Do Options Traders Know Something About Celldex (CLDX) Stock We Don't? Zacks
Jan-04-21 08:01AM	Celldex Appoints Freddy A. Jimenez, Esq. as Senior Vice President and General Counsel GlobeNewswire +9.02%
Dec-23-20 06:55AM	These 5 Small-Cap Healthcare Stocks Gained the Most in 2020 Motley Fool
Dec-09-20 08:01AM	Celldex Doses First Patient in Phase 1b Study of CDX-0159 in Chronic Inducible Urticaria GlobeNewswire -5.63%
Nov-30-20 04:01PM	Celldex Therapeutics to Present at 3rd Annual Evercore ISI HealthCONx Conference GlobeNewswire
Nov-27-20 12:30AM	Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation Simply Wall St.
Nov-09-20 08:01AM	Celldex Presents Data from Oncology Portfolio at SITC 2020 GlobeNewswire
Nov-05-20 05:55PM	Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM	Celldex Provides Corporate Update and Reports Third Quarter 2020 Results GlobeNewswire
Nov-03-20 12:31PM	Will Celldex Therapeutics (CLDX) Report Negative Q3 Earnings? What You Should Know Zacks
Oct-15-20 08:14PM	2 Biotech Stocks That Keep on Climbing Motley Fool -5.45%
Oct-14-20 11:32AM	Celldex Initiates Early-Stage Antibody Study for Skin Disorder Zacks
Oct-13-20 08:01AM	Celldex Therapeutics Initiates Phase 1b Study of CDX-0159 in Chronic Spontaneous Urticaria GlobeNewswire
Oct-06-20 06:09PM	Hedge Funds Have Never Been This Bullish On Celldex Therapeutics, Inc. (CLDX) Insider Monkey +19.47%
Sep-29-20 08:58AM	Is the Options Market Predicting a Spike in Celldex Therapeutics (CLDX) Stock? Zacks
Sep-10-20 04:01PM	Celldex Therapeutics to Present at Upcoming Healthcare Conferences GlobeNewswire
Aug-25-20 01:25PM	The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics Zacks
Aug-24-20 08:01AM	Celldex Therapeutics Initiates Phase 1 Study of New Bispecific Product Candidate CDX-527 in Solid Tumors GlobeNewswire

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Martin Samuel Bates	SVP and CFO	Dec 23	Option Exercise	5.68	7,000	39,729	33,878	Dec 28 04:02 PM
Martin Samuel Bates	SVP and CFO	Dec 23	Sale	42.00	9,500	399,000	24,378	Dec 28 04:02 PM
Crowley Elizabeth	Sr. VP &CPDO	Dec 08	Option Exercise	9.02	4,000	36,066	8,726	Dec 10 04:02 PM
Heath-Chiozzi Margo	SVP of Regulatory Affairs	Dec 08	Option Exercise	2.78	600	1,668	11,847	Dec 10 04:02 PM
Cavanaugh Sarah	SVP of Corp Affairs & Admin.	Dec 08	Option Exercise	10.03	7,323	73,481	7,731	Dec 10 04:03 PM
Heath-Chiozzi Margo	SVP of Regulatory Affairs	Dec 08	Sale	40.00	600	24,000	11,247	Dec 10 04:02 PM
Crowley Elizabeth	Sr. VP &CPDO	Dec 08	Sale	40.00	4,000	160,000	4,726	Dec 10 04:02 PM
Cavanaugh Sarah	SVP of Corp Affairs & Admin.	Dec 08	Sale	40.00	7,323	292,920	408	Dec 10 04:03 PM
Martin Samuel Bates	SVP and CFO	Nov 15	Option Exercise	5.68	7,000	39,729	36,378	Nov 17 04:02 PM
Martin Samuel Bates	SVP and CFO	Nov 15	Sale	43.57	9,500	413,883	26,878	Nov 17 04:02 PM
Young Diane C.	SVP, Chief Medical Officer	Nov 12	Option Exercise	10.38	4,600	47,748	6,715	Nov 16 04:02 PM
Young Diane C.	SVP, Chief Medical Officer	Nov 12	Sale	42.94	4,600	197,529	2,115	Nov 16 04:02 PM
Crowley Elizabeth	Sr. VP &CPDO	Nov 01	Option Exercise	2.78	8,555	23,783	9,043	Nov 03 04:02 PM
Heath-Chiozzi Margo	SVP of Regulatory Affairs	Nov 01	Option Exercise	2.78	600	1,668	11,847	Nov 03 04:02 PM
Cavanaugh Sarah	SVP of Corp Affairs & Admin.	Nov 01	Option Exercise	8.03	5,956	47,852	7,731	Nov 03 04:02 PM
Heath-Chiozzi Margo	SVP of Regulatory Affairs	Nov 01	Sale	41.71	600	25,026	11,247	Nov 03 04:02 PM
Crowley Elizabeth	Sr. VP &CPDO	Nov 01	Sale	43.29	4,317	186,874	4,726	Nov 03 04:02 PM
Cavanaugh Sarah	SVP of Corp Affairs & Admin.	Nov 01	Sale	43.26	7,323	316,804	408	Nov 03 04:02 PM
Heath-Chiozzi Margo	SVP of Regulatory Affairs	Aug 11	Option Exercise	9.02	10,000	90,165	11,247	Aug 13 06:59 AM
Jimenez Freddy A.	SVP & General Counsel	Aug 11	Buy	46.28	430	19,900	430	Aug 13 06:58 AM
Martin Samuel Bates	SVP and CFO	Aug 10	Option Exercise	5.78	21,381	123,688	30,060	Aug 12 10:00 AM
Martin Samuel Bates	SVP and CFO	Aug 10	Sale	45.25	2,738	123,894	18,981	Aug 12 10:00 AM
Marucci Anthony S	President & CEO	Aug 05	Option Exercise	42.00	3,537	148,554	27,231	Aug 09 07:21 AM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience